MedPath

Effect of Moxifloxacin(0.5mg) instillation in anterior chamber in Phacoemulsification surgery

Not Applicable
Conditions
Health Condition 1: H259- Unspecified age-related cataract
Registration Number
CTRI/2020/06/025909
Lead Sponsor
Mohit kumar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age group (40-80yr)

2. Senile cataract in patients associated with visual impairment.

3. Grade I - III cataract (grading will be done according to LOCS III classification

Exclusion Criteria

1.Patients with any ocular pathology other than cataracts such as retinal vascular disorders and ARMD and Diabetic retinopathy .

2. Ocular condition like glaucoma and uveitis .

3.Those with other media opacities corneal or vitreous .

4.Subjects with traumatic cataract, complicated cataract , grade 4 cataract

5.Patient with known case of diabetes mellitus

6.Patients who underwent previous intraocular surgery other than cataract.

7.Any intraoperative complication

1.Patients with any ocular pathology other than cataracts such as retinal vascular disorders and ARMD and Diabetic retinopathy .

2. Ocular condition like glaucoma and uveitis .

3.Those with other media opacities corneal or vitreous .

4.Subjects with traumatic cataract, complicated cataract , grade 4 cataract

5.Patient with known case of diabetes mellitus

6.Patients who underwent previous intraocular surgery other than cataract.

7.Any intraoperative complication

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to study the effect of intracameral moxifloxacin(0.5mg) on corneal endothelium in phacoemulsification surgeryTimepoint: Corneal endothelial cell count on day 1, 7 and 21 after surgery.
Secondary Outcome Measures
NameTimeMethod
TO COMPARE THE CHANGE IN MORPHOLOGY OF CORNEA â?? ENDOTHELIAL CELL COUNT , HEXAGONALITY, COEFICIENT OF VARIATION IN CELL AREA, CORNEAL THICKNESS DUE TO USE OF INTRACAMERAL MOXIFLOXACIN IN PHACOEMULSIFICATION SURGERY.Timepoint: day 1, 7 and 21 after surgery
© Copyright 2025. All Rights Reserved by MedPath